# OnKure Therapeutics, Inc.: overview

OKUR · Nasdaq · CIK 1637715 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/okur.md) · [Financials](/companies/okur/financials.md) · [Filings](/companies/okur/filings.md) · [Insiders](/companies/okur/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(36.55)](/filings/0001193125-25-269540.md) | not reported | [(1.19)](/filings/0001193125-26-206345.md) | [(1.14)](/filings/0001193125-26-332773.md) | [(1.09)](/filings/0001193125-25-269540.md) | not reported | [(1.11)](/filings/0001193125-26-206345.md) | [(0.31)](/filings/0001193125-26-332773.md) |
| Free cash flow | $m | [(10.7) d](/filings/0001193125-25-269540.md) | [(23.4) d](/filings/0001193125-26-104147.md) | [(14.0)](/filings/0001193125-26-206345.md) | [(13.3) d](/filings/0001193125-26-332773.md) | [(13.0) d](/filings/0001193125-25-269540.md) | [(11.5) d](/filings/0001193125-26-104147.md) | [(12.9)](/filings/0001193125-26-206345.md) | [(10.4) d](/filings/0001193125-26-332773.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | [0.0](/filings/0000950170-25-036252.md) | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(2.19)](/filings/0000950170-23-009978.md) | [(2.12)](/filings/0000950170-24-038009.md) | [(124.41)](/filings/0000950170-25-036252.md) | [(15.28)](/filings/0001193125-26-104147.md) | [(4.40)](/filings/0001193125-26-104147.md) |
| Free cash flow | $m | [(38.2)](/filings/0000950170-23-009978.md) | [(47.7)](/filings/0000950170-24-038009.md) | [(34.8)](/filings/0000950170-25-036252.md) | [(51.2)](/filings/0001193125-26-104147.md) | [(51.9)](/filings/0001193125-26-104147.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/okur/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $18.2m | 3,998,333 |  | Unchanged |
| [BVF INC/IL](/funds/1056807.md) | 2026-06-30 | $14.8m | 3,235,778 |  | Added +1,256,806 |
| [ACORN CAPITAL ADVISORS, LLC](/funds/2054410.md) | 2026-06-30 | $12.9m | 2,839,674 |  | Unchanged |
| [StepStone Group LP](/funds/1502287.md) | 2026-06-30 | $12.1m | 2,660,612 |  | Unchanged |
| [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $10.2m | 2,238,684 |  | Reduced −196,257 |
| [Vivo Capital, LLC](/funds/1674712.md) | 2026-06-30 | $8.8m | 1,927,710 |  | Unchanged |
| [Vestal Point Capital, LP](/funds/1974915.md) | 2026-06-30 | $8.3m | 1,825,699 |  | Reduced −14,120 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $6.8m | 1,499,845 |  | Added +1,450,258 |
| [Trails Edge Capital Partners, LP](/funds/2077247.md) | 2026-06-30 | $6.6m | 1,438,456 |  | New +1,438,456 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $6.6m | 1,437,039 |  | Added +854,562 |

## Recent filings

[All 399 filings](/companies/okur/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-13 | 22:22 ET | [8-K](/filings/0001193125-26-347315.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-347315 |
| 2026-08-04 | 20:10 ET | [8-K](/filings/0001193125-26-332809.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-332809 |
| 2026-08-04 | 20:05 ET | [10-Q](/filings/0001193125-26-332773.md) | Quarterly report, period 2026-06-30 | 0001193125-26-332773 |
| 2026-06-04 | 20:15 ET | [8-K](/filings/0001193125-26-257423.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-257423 |
| 2026-05-05 | 20:10 ET | [8-K](/filings/0001193125-26-206396.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-206396 |
| 2026-05-05 | 20:05 ET | [10-Q](/filings/0001193125-26-206345.md) | Quarterly report, period 2026-03-31 | 0001193125-26-206345 |
| 2026-04-21 | 20:15 ET | [DEF 14A](/filings/0001140361-26-015903.md) | Proxy statement, period 2026-06-03 | 0001140361-26-015903 |
| 2026-04-07 | 01:14 ET | [SCHEDULE 13D](/filings/0001193125-26-146025.md) | Ownership report, active investor | 0001193125-26-146025 |
| 2026-03-30 | 10:01 ET | [8-K](/filings/0001193125-26-130283.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-130283 |
| 2026-03-12 | 20:10 ET | [10-K](/filings/0001193125-26-104147.md) | Annual report, period 2025-12-31 | 0001193125-26-104147 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-104147.md), filed Mar 12, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1637715
- Tickers: OKUR
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.